Navigation Links
Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
Date:1/16/2012

SOMERSET, N.J., Jan. 16, 2012 /PRNewswire/ -- Terumo Americas Holding, Inc. (TAH), a U.S. subsidiary of Japan's Terumo Corporation, one of the world's leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations, today announced that it has acquired Onset Medical Corporation ("Onset"), an innovative medical device company located in Irvine, CA, that focuses on developing first-in-class access sheath technology designed for multiple, minimally invasive clinical applications in cardiology and urology.

Using its proprietary Controlled Deployment Technology (CDT) platform, Onset has developed the smallest sheath profiles with the largest internal diameters of any available access sheath to protect against unnecessary access site or arterial trauma for the patient. Onset's Associates will join with TAH subsidiary Terumo Medical Corporation as part of its Terumo Interventional Systems (TIS) business unit, where the CDT platform will complement TIS' complete product line of industry leading entry site management and lesion access technologies.

Terumo customers will have access to Onset's complete product lines.  The SoloPath™ Balloon Expandable Transfemoral and Transseptal Catheters' expandable and collapsable sheath technology allows TIS to enter the global structural heart and aneurysmal repair markets, providing an access platform for complex, large-bore procedures including Transcatheter Aortic Valve Implantation (TAVI), Thoracic Endovascular Aortic/Aneurysm Repair (TVAR) and Endovascular Aneurysm/Aortic Repair (EVAR).  The Pathway™ Balloon Expandable PCNL Sheath and Pathway™ Balloon Expandable Ureteral Access Sheath provide physicians with a one-step option for performing procedures such as Percutaneous Nephrolithotomy in the removal of large renal calculi (kidney stones).

"We welcome Onset to the Terumo family and look forward to providing our customers with current and future products based on the exciting CDT platform, which represents a tremendous complement to our overall value proposition as the leaders in entry site management and lesion access," said James Rushworth, Senior Vice President and General Manager, Terumo Medical Corporation and President, Onset Medical Corporation.  "CDT literally changes the way physicians enter the vascular system and manage the access site, while allowing them to achieve easier, safer access to the target lesion in a variety of clinical applications.  This strategic acquisition reinforces our commitment to pursuing unique technologies that meet the specialized needs of our customers and contribute to better outcomes for their patients."

As a global leader in vascular access management, TIS can effectively maximize the potential of the CDT-based platform when compared with competitors who do not specialize in entry site management.

"When Terumo approached us, it quickly became clear that they were the established leader in entry site management and the best company to commercialize our sheath technology on a global scale," said Joseph Bishop, Vice President and Chief Operating Officer, Onset Medical Corporation. "It is gratifying to know that our unique devices will immediately strengthen their core capability and will be featured prominently among other class-leading technologies that drive better patient outcomes."

For more information, contact Robert Murphy, The Storch-Murphy Group, 908.276.0777.    

Terumo Interventional Systems

Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures. Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4.0 billion in sales and operations in more than 160 nations.  Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.  Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.  Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:  JP) and is a component of the Nikkei 225, Japan's leading stock index.


'/>"/>
SOURCE Terumo Americas Holding, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
10. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
11. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... With a heatwave currently bearing down on Northern California pushing temperatures to the ... swimsuit ready is easy with laser hair removal. , The process of summer waxing ... routine when all you want to do is get out, dive in and cool off. ...
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/24/2017)... , ... June 24, 2017 , ... Doorknobs are for ... security, such as getting a guard dog or having an alarm system installed. But ... secure against forced entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... is needed and will ultimately do significant harm to people with all chronic ... , "While it leaves in place the Affordable Care Act (ACA) requirement ...
Breaking Medicine News(10 mins):